Rapid progress in neuroimaging technologies fuels central nervous system translational medicine

Linghui Kong; Qian He; Qiu Li; Rudy Schreiber; Kenneth I. Kaitin; Liming Shao

doi:10.1016/j.drudis.2023.103485

Rapid progress in neuroimaging technologies fuels central nervous system translational medicine

Linghui Kong, Qian He, Qiu Li, Rudy Schreiber, Kenneth I. Kaitin, Liming Shao^*

^*Corresponding author for this work

Research output: Contribution to journal › (Systematic) Review article › peer-review

Abstract

Central nervous system (CNS) drug discovery suffers from high attrition rates; translational neuroscience approaches aiming to reduce these high rates include the use of brain imaging technologies. However, there is a need to better understand what methods are being used and for what diseases and purposes. Our analysis of the literature found that magnetic resonance imaging (MRI), positron emission tomography (PET), and single-photon emission computed tomography (SPECT) were the neuroimaging techniques used most often in clinical trials for the most prevalent CNS diseases: Alzheimer's disease (AD), Parkinson's disease (PD), depression, and schizophrenia. Moreover, the number of initiated clinical trials using MRI, PET, and SPECT increased over the period 1981-2021. Such insights indicate that the significant increase in the use of neuroimaging studies could decrease the attrition of novel drug candidates in late clinical development.

Original language	English
Article number	103485
Number of pages	9
Journal	Drug Discovery Today
Volume	28
Issue number	3
Early online date	Jan 2023
DOIs	https://doi.org/10.1016/j.drudis.2023.103485
Publication status	Published - Mar 2023

Access to Document

10.1016/j.drudis.2023.103485

Cite this

@article{a2ba3a397f5247e5af385423dad44adb,

title = "Rapid progress in neuroimaging technologies fuels central nervous system translational medicine",

abstract = "Central nervous system (CNS) drug discovery suffers from high attrition rates; translational neuroscience approaches aiming to reduce these high rates include the use of brain imaging technologies. However, there is a need to better understand what methods are being used and for what diseases and purposes. Our analysis of the literature found that magnetic resonance imaging (MRI), positron emission tomography (PET), and single-photon emission computed tomography (SPECT) were the neuroimaging techniques used most often in clinical trials for the most prevalent CNS diseases: Alzheimer's disease (AD), Parkinson's disease (PD), depression, and schizophrenia. Moreover, the number of initiated clinical trials using MRI, PET, and SPECT increased over the period 1981-2021. Such insights indicate that the significant increase in the use of neuroimaging studies could decrease the attrition of novel drug candidates in late clinical development.",

author = "Linghui Kong and Qian He and Qiu Li and Rudy Schreiber and Kaitin, {Kenneth I.} and Liming Shao",

year = "2023",

month = mar,

doi = "10.1016/j.drudis.2023.103485",

language = "English",

volume = "28",

journal = "Drug Discovery Today",

issn = "1359-6446",

publisher = "Elsevier Limited",

number = "3",

}

TY - JOUR

T1 - Rapid progress in neuroimaging technologies fuels central nervous system translational medicine

AU - Kong, Linghui

AU - He, Qian

AU - Li, Qiu

AU - Schreiber, Rudy

AU - Kaitin, Kenneth I.

AU - Shao, Liming

PY - 2023/3

Y1 - 2023/3

N2 - Central nervous system (CNS) drug discovery suffers from high attrition rates; translational neuroscience approaches aiming to reduce these high rates include the use of brain imaging technologies. However, there is a need to better understand what methods are being used and for what diseases and purposes. Our analysis of the literature found that magnetic resonance imaging (MRI), positron emission tomography (PET), and single-photon emission computed tomography (SPECT) were the neuroimaging techniques used most often in clinical trials for the most prevalent CNS diseases: Alzheimer's disease (AD), Parkinson's disease (PD), depression, and schizophrenia. Moreover, the number of initiated clinical trials using MRI, PET, and SPECT increased over the period 1981-2021. Such insights indicate that the significant increase in the use of neuroimaging studies could decrease the attrition of novel drug candidates in late clinical development.

AB - Central nervous system (CNS) drug discovery suffers from high attrition rates; translational neuroscience approaches aiming to reduce these high rates include the use of brain imaging technologies. However, there is a need to better understand what methods are being used and for what diseases and purposes. Our analysis of the literature found that magnetic resonance imaging (MRI), positron emission tomography (PET), and single-photon emission computed tomography (SPECT) were the neuroimaging techniques used most often in clinical trials for the most prevalent CNS diseases: Alzheimer's disease (AD), Parkinson's disease (PD), depression, and schizophrenia. Moreover, the number of initiated clinical trials using MRI, PET, and SPECT increased over the period 1981-2021. Such insights indicate that the significant increase in the use of neuroimaging studies could decrease the attrition of novel drug candidates in late clinical development.

U2 - 10.1016/j.drudis.2023.103485

DO - 10.1016/j.drudis.2023.103485

M3 - (Systematic) Review article

C2 - 36623797

SN - 1359-6446

VL - 28

JO - Drug Discovery Today

JF - Drug Discovery Today

IS - 3

M1 - 103485

ER -